Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis
- PMID: 27342249
- PMCID: PMC5474304
- DOI: 10.1016/j.radonc.2016.05.022
Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis
Abstract
Background: Owing to its physical properties, intensity-modulated proton therapy (IMPT) used for patients with oropharyngeal carcinoma has the ability to reduce the dose to organs at risk compared to intensity-modulated radiotherapy (IMRT) while maintaining adequate tumor coverage. Our aim was to compare the clinical outcomes of these two treatment modalities.
Methods: We performed a 1:2 matching of IMPT to IMRT patients. Our study cohort consisted of IMPT patients from a prospective quality of life study and consecutive IMRT patients treated at a single institution during the period 2010-2014. Patients were matched on unilateral/bilateral treatment, disease site, human papillomavirus status, T and N status, smoking status, and receipt of concomitant chemotherapy. Survival analyzes were performed using a Cox model and binary toxicity endpoints using a logistic regression analysis.
Results: Fifty IMPT and 100 IMRT patients were included. The median follow-up time was 32months. There were no imbalances in patient/tumor characteristics except for age (mean age 56.8years for IMRT patients and 61.1years for IMPT patients, p-value=0.010). Statistically significant differences were not observed in overall survival (hazard ratio (HR)=0.55; 95% confidence interval (CI): 0.12-2.50, p-value=0.44) or in progression-free survival (HR=1.02; 95% CI: 0.41-2.54; p-value=0.96). The age-adjusted odds ratio (OR) for the presence of a gastrostomy (G)-tube during treatment for IMPT vs IMRT were OR=0.53; 95% CI: 0.24-1.15; p-value=0.11 and OR=0.43; 95% CI: 0.16-1.17; p-value=0.10 at 3months after treatment. When considering the pre-planned composite endpoint of grade 3 weight loss or G-tube presence, the ORs were OR=0.44; 95% CI: 0.19-1.0; p-value=0.05 at 3months after treatment and OR=0.23; 95% CI: 0.07-0.73; p-value=0.01 at 1year after treatment.
Conclusion: Our results suggest that IMPT is associated with reduced rates of feeding tube dependency and severe weight loss without jeopardizing outcome. Prospective multicenter randomized trials are needed to validate such findings.
Keywords: Chemoradiation; Human papilloma virus; Intensity-modulated proton therapy; Intensity-modulated radiotherapy; Oropharyngeal cancer; Radiation therapy.
Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.
Figures
Similar articles
-
Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.Oral Oncol. 2019 Jan;88:66-74. doi: 10.1016/j.oraloncology.2018.11.015. Epub 2018 Nov 21. Oral Oncol. 2019. PMID: 30616799 Free PMC article. Review.
-
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.JAMA Netw Open. 2022 Nov 1;5(11):e2241538. doi: 10.1001/jamanetworkopen.2022.41538. JAMA Netw Open. 2022. PMID: 36367724 Free PMC article.
-
Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.Med Dosim. 2016 Autumn;41(3):189-94. doi: 10.1016/j.meddos.2016.01.002. Epub 2016 May 4. Med Dosim. 2016. PMID: 27158021
-
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.JAMA Netw Open. 2021 Jun 1;4(6):e2113205. doi: 10.1001/jamanetworkopen.2021.13205. JAMA Netw Open. 2021. PMID: 34143193 Free PMC article.
-
Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy.Curr Treat Options Oncol. 2021 Jun 4;22(6):54. doi: 10.1007/s11864-021-00847-y. Curr Treat Options Oncol. 2021. PMID: 34086150 Free PMC article. Review.
Cited by
-
Simulation of dose distribution and secondary particle production in proton therapy of brain tumor.Rep Pract Oncol Radiother. 2020 Nov-Dec;25(6):927-933. doi: 10.1016/j.rpor.2020.08.015. Epub 2020 Oct 3. Rep Pract Oncol Radiother. 2020. PMID: 33088228 Free PMC article.
-
Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?Clin Transl Radiat Oncol. 2017 Nov 4;8:4-11. doi: 10.1016/j.ctro.2017.10.005. eCollection 2018 Jan. Clin Transl Radiat Oncol. 2017. PMID: 29594236 Free PMC article. Review.
-
Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care.JCO Oncol Pract. 2020 Sep;16(9):e966-e976. doi: 10.1200/JOP.19.00437. Epub 2020 Apr 17. JCO Oncol Pract. 2020. PMID: 32302271 Free PMC article.
-
Immune System Dose With Proton Versus Photon Radiotherapy for Treatment of Locally Advanced NSCLC.Int J Part Ther. 2024 Apr 23;12:100016. doi: 10.1016/j.ijpt.2024.100016. eCollection 2024 Jun. Int J Part Ther. 2024. PMID: 38832321 Free PMC article.
-
Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.Oral Oncol. 2019 Jan;88:66-74. doi: 10.1016/j.oraloncology.2018.11.015. Epub 2018 Nov 21. Oral Oncol. 2019. PMID: 30616799 Free PMC article. Review.
References
-
- Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources